Edmond de Rothschild (ERES IV), Advised by Elyan Partners, Acquires Majority Stake in Oncodesign Services

July 1, 2022

Edmond de Rothschild Equity Strategies IV SLP (ERES IV), advised by Elyan Partners, acquired a majority stake in Oncodesign Services (ODS), taking control of a 61.58% block and announcing a planned simplified tender offer (OPAS) for the remaining shares. The transaction separates Oncodesign's Services and Biotech businesses and positions ODS for accelerated organic growth and potential bolt-on acquisitions under continued management involvement from founder Philippe Genne and CEO Fabrice Viviani.

Buyers
Edmond de Rothschild Equity Strategies IV SLP (ERES IV), Elyan Partners
Targets
Oncodesign Services (Oncodesign / ODS)
Sellers
Philippe Genne (via holding P.C.G.) and other principal shareholders, certain managers and minority shareholders
Location
Bourgogne-Franche-Comté, France
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.